Abstract: Compounds of the formula I in which R1 denotes A, Ar, Cyc, Het, COA or CN, R2 denotes SO2A, SOA, SA, SO2NHA, SO2NA2, S(?NH,?O)A, S(?NH)2A, NO2, Hal, CN, A, Het1, COOH or COOA, R3 denotes H or Hal, R4 denotes H or Hal, n denotes 1, 2 or 3, A denotes unbranched or branched alkyl having 1-6 C-atoms, Cyc denotes cyclic alkyl with 3 to 7 C-atoms, Ar denotes phenyl, Het denotes a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O, and/or S atoms, Het1 denotes a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O, and/or S atoms, and Hal denotes F, Cl, Br, or I, are inhibitors of HIF-2?, and can be employed for the treatment of diseases such as cancer.

Abstract: Compounds of the formula I are inhibitors of HIF-2?, and can be employed for the treatment of diseases such as cancer.

Abstract: Compounds of the formula I are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer. R1 denotes H, Hal, CF3, NO2, A, [C(R3)2]nN(R3)2, [C(R3)2]nHet1, OR3, O[C(R3)2]nN(R3)2, O[C(R3)2]nS(O)mR3, O[C(R3)2]nCOOR3, O[C(R3)2]nCOON(R3)2, O[C(R3)2]nHet1, O[C(R3)2]nN(R3)Het1, O[C(R3)2]nPh, or O[C(R3)2]nCyc. R2 denotes H or CH3. R3 denotes H or A. V denotes H or Hal. X denotes O or N(R3). Y denotes phenylene, pyridin-diyl, thiophen-diyl, 1,3-thiazol-diyl or pyrazol-diyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal and/or A. Z denotes CON(R3)2, phenyl, Het4 or —O-A.

Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation.

Abstract: Compounds of the formula I in which R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, multiple sclerosis, cardiovascular diseases, central nervous system injury and different forms of inflammation.

Abstract: Compounds of the formula Ia or of the formula Ib in which X, Y, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.

Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation.

Abstract: Compounds of the formula I in which R1 denotes A, Ar, Cyc, Het, COA or CN, R2 denotes SO2A, SOA, SA, SO2NHA, SO2NA2, S(?NH,?O)A, S(?NH)2A, NO2, Hal, CN, A, Het1, COOH or COOA, R3 denotes H or Hal, R4 denotes H or Hal, n denotes 1, 2 or 3, A denotes unbranched or branched alkyl having 1-6 C-atoms, Cyc denotes cyclic alkyl with 3 to 7 C-atoms, Ar denotes phenyl, Het denotes a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O, and/or S atoms, Het1 denotes a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O, and/or S atoms, and Hal denotes F, Cl, Br, or I, are inhibitors of HIF-2?, and can be employed for the treatment of diseases such as cancer.

Abstract: Compounds of the formula I in which X, Q, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.

Abstract: Compounds of the formula Ia or of the formula Ib in which X, Y, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.

Abstract: Compounds of the formula Ia or of the formula Ib in which X, Y, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.

Abstract: Compounds of the formula I in which X, Q, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.

Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation.

Abstract: Compounds of the formula Ia or of the formula Ib in which X, Y, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.

Abstract: Compounds of the formula I in which Z, W, Q, R and Y have the meanings indicated in claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.

Abstract: Compounds of the formula Ia or of the formula Ib in which X, Y, R1 and R2 have the meanings indicated in claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.

Abstract: Compounds of the formula I in which X, Y, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.

Abstract: Substituted quinoxaline derivatives are useful for the prevention and/or treatment of medical conditions known as hyperproliferative diseases. The compounds are also useful for medical conditions that are affected by inhibiting 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB). Further, the compounds are useful for the prevention and/or treatment of cancer.

Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitization of cancer cells to anticancer agents and/or ionizing radiation.

Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation.